|
1）Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987; 51: 919-28
|
|
|
|
2）Theadom A, Rodrigues M, Roxburgh R, et al. Prevalence of muscular dystrophies: a systematic literature review. Neuroepidemiology. 2014; 43: 259-68
|
|
|
|
|
|
3）Koenig M, Beggs AH, Moyer M, et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet. 1989; 45: 498-506
|
|
|
|
|
|
4）Aartsma-Rus A, Fokkema I, Verschuuren J, et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat. 2009; 30: 293-9
|
|
|
|
|
|
5）Monaco AP, Bertelson CJ, Liechti-Gallati S, et al. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 1988; 2: 90-5
|
|
|
|
|
|
6）Tuffery-Giraud S, Béroud C, Leturcq F, et al. Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. Hum Mutat. 2009; 30: 934-45
|
|
|
|
|
|
7）日本神経学会，日本小児神経学会，国立精神・神経医療研究センター，監修，「デュシェンヌ型筋ジストロフィー診療ガイドライン」作成委員会，編．デュシェンヌ型筋ジストロフィー診療ガイドライン2014. 東京: 南江堂; 2014
|
|
|
|
|
|
8）Summerton J, Stein D, Huang SB, et al. Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev. 1997; 7: 63-70
|
|
|
|
|
|
9）Hudziak RM, Barofsky E, Barofsky DF, et al. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev. 1996; 6: 267-72
|
|
|
|
|
|
10）Aoki Y, Nagata T, Yokota T, et al. Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice. Hum Mol Genet. 2013; 22: 4914-28
|
|
|
|
|
|
11）Aoki Y, Nakamura A, Yokota T, et al. In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther. 2010; 18: 1995-2005
|
|
|
|
|
|
12）Aoki Y, Yokota T, Nagata T, et al. Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci U S A. 2012; 109: 13763-8
|
|
|
|
|
|
13）Yokota T, Lu QL, Partridge T, et al. Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol. 2009; 65: 667-76
|
|
|
|
|
|
14）Yokota T, Nakamura A, Nagata T, et al. Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic Acid Ther. 2012; 22: 306-15
|
|
|
|
|
|
15）Echigoya Y, Lee J, Rodrigues M, et al. Mutation types and aging differently affect revertant fiber expansion in dystrophic mdx and mdx52 mice. PLoS One. 2013; 8: e69194
|
|
|
|
|
|
16）Saito T, Nakamura A, Aoki Y, et al. Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient. PLoS One. 2010; 5: e12239
|
|
|
|
|
|
17）Voit T, Topaloglu H, Straub V, et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol. 2014; 13: 987-96
|
|
|
|
|
|
18）Goemans NM, Tulinius M, van den Akker JT, et al. Systemic administration of PRO051 in Duchenneʼs muscular dystrophy. N Engl J Med. 2011; 364 : 1513-22
|
|
|
|
|
|
19）Mendell JR, Rodino-Klapac LR, Sahenk Z, et al; Eteplirsen Study Group. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013; 74: 637-47
|
|
|
|
|
|
20）Ezzat K, Aoki Y, Koo T, et al. Self-Assembly into Nanoparticles Is Essential for Receptor Mediated Uptake of Therapeutic Antisense Oligonucleotides. Nano Lett. 2015; 15: 4364-73
|
|
|
|
|
|
21）青木吉嗣，武田伸一．デュシェンヌ型筋ジストロフィーに対するエクソンスキップ療法．生体の科学．東京: 医学書院; 2011. p.128-33
|
|
|
|
|